Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission

Phillip C. Nguyen; Kate Manos; Chun Y. Fong; Anthony P. Schwarer; Ing S. Tiong; Andrew H. Wei; David Kliman; David J. Curtis

doi:10.1111/imj.15564

Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission

Phillip C. Nguyen, Kate Manos, Chun Y. Fong, Anthony P. Schwarer, Ing S. Tiong, Andrew H. Wei, David Kliman, David J. Curtis

Australian Centre for Blood Diseases

Research output: Contribution to journal › Article › Research › peer-review

Abstract

The benefits of non-myeloablative stem cell transplant in older patients with acute myeloid leukaemia are unclear. We compare the long-term outcomes of this regimen in those aged 55–65 years in first remission with a chemotherapy only cohort that achieved durable morphologic remission. Five-year overall survival was similar (32% vs 33%, P = 0.90), as was relapse-free survival (23% vs 20%, P = 0.37). There was a trend for decreased relapse that was balanced against increased non-relapse mortality with transplantation.

Original language	English
Pages (from-to)	1954-1958
Number of pages	5
Journal	Internal Medicine Journal
Volume	51
Issue number	11
DOIs	https://doi.org/10.1111/imj.15564
Publication status	Published - Nov 2021

Keywords

acute myeloid leukemia
consolidation chemotherapy
elderly
haemopoietic stem cell transplantation
relapse
survival

Access to Document

10.1111/imj.15564

Cite this

@article{7a1116b2777f40edbc1e5af816f65836,

title = "Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission",

abstract = "The benefits of non-myeloablative stem cell transplant in older patients with acute myeloid leukaemia are unclear. We compare the long-term outcomes of this regimen in those aged 55–65 years in first remission with a chemotherapy only cohort that achieved durable morphologic remission. Five-year overall survival was similar (32% vs 33%, P = 0.90), as was relapse-free survival (23% vs 20%, P = 0.37). There was a trend for decreased relapse that was balanced against increased non-relapse mortality with transplantation.",

keywords = "acute myeloid leukemia, consolidation chemotherapy, elderly, haemopoietic stem cell transplantation, relapse, survival",

author = "Nguyen, {Phillip C.} and Kate Manos and Fong, {Chun Y.} and Schwarer, {Anthony P.} and Tiong, {Ing S.} and Wei, {Andrew H.} and David Kliman and Curtis, {David J.}",

note = "Funding Information: Funding: David J Curtis is funded by a NHMRC Senior Research Fellowship APP1139466. Publisher Copyright: {\textcopyright} 2021 Royal Australasian College of Physicians.",

year = "2021",

month = nov,

doi = "10.1111/imj.15564",

language = "English",

volume = "51",

pages = "1954--1958",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "Wiley-Blackwell",

number = "11",

}

TY - JOUR

T1 - Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission

AU - Nguyen, Phillip C.

AU - Manos, Kate

AU - Fong, Chun Y.

AU - Schwarer, Anthony P.

AU - Tiong, Ing S.

AU - Wei, Andrew H.

AU - Kliman, David

AU - Curtis, David J.

PY - 2021/11

Y1 - 2021/11

N2 - The benefits of non-myeloablative stem cell transplant in older patients with acute myeloid leukaemia are unclear. We compare the long-term outcomes of this regimen in those aged 55–65 years in first remission with a chemotherapy only cohort that achieved durable morphologic remission. Five-year overall survival was similar (32% vs 33%, P = 0.90), as was relapse-free survival (23% vs 20%, P = 0.37). There was a trend for decreased relapse that was balanced against increased non-relapse mortality with transplantation.

AB - The benefits of non-myeloablative stem cell transplant in older patients with acute myeloid leukaemia are unclear. We compare the long-term outcomes of this regimen in those aged 55–65 years in first remission with a chemotherapy only cohort that achieved durable morphologic remission. Five-year overall survival was similar (32% vs 33%, P = 0.90), as was relapse-free survival (23% vs 20%, P = 0.37). There was a trend for decreased relapse that was balanced against increased non-relapse mortality with transplantation.

KW - acute myeloid leukemia

KW - consolidation chemotherapy

KW - elderly

KW - haemopoietic stem cell transplantation

KW - relapse

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85119214889&partnerID=8YFLogxK

U2 - 10.1111/imj.15564

DO - 10.1111/imj.15564

M3 - Article

C2 - 34796631

AN - SCOPUS:85119214889

SN - 1444-0903

VL - 51

SP - 1954

EP - 1958

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 11

ER -

Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission

Abstract

Keywords

Access to Document

Other files and links

Curing blood cancers: rapid translation from target to drug to clinic

Cite this

Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission

Abstract

Keywords

Access to Document

Other files and links

Projects

Curing blood cancers: rapid translation from target to drug to clinic

Cite this